Featured image for post: Elan Cohen, PhD – NJ Licensure

Elan Cohen, PhD – NJ Licensure

Berlin, NJ (May 23, 2018) – Hassman Research Institute (HRI) is proud to announce that Elan Cohen, Ph.D. has recently earned his Psychology license in New Jersey, and as such, can fulfill the role of Principal Investigator (PI) for numerous clinical trials focused on Central Nervous System (CNS) and other related indications. Although Dr. Cohen has been licensed as a Psychologist for over 10 years in the state of Pennsylvania, his licensure in New Jersey, where HRI is located, allows for the opportunity to have Dr. Cohen serve as a PI for wider span of sponsor studies. Dr. Cohen has worked at HRI since 2016 in the role of Sub-Investigator and Lead Psychometrician for Phase I-IV CNS and medically-focused clinical trials.

Upon earning his Ph.D. in Counseling Psychology from Indiana State University, Dr. Cohen expanded his psychotherapeutic and psychiatric diagnostic and severity psychometric rating expertise as a Psychologist at the University of Pennsylvania Counseling and Psychological Services Center. He worked at the university for over seven years where he also conducted research on treatment efficacy and taught undergraduate and graduate level psychology courses.

After his work at the university, Dr. Cohen held the positions of Sub-Investigator, Site Director, and Psychometric Rater at CNS Research Instituite, a private psychiatric outpatient and inpatient clinical trial site. Dr. Cohen’s pharma work expanded as Clinical Manager and then Associate Director of Clinical Teams and Operations at MedAvante, followed by his work as Director of the Clinical Assessment Technologies Department at the CRO, Worldwide Clinical Trials. In these positions, Dr. Cohen incorporated clinical and operational pharmaceutical study needs to develop comprehensive and efficient global training programs, psychiatric remote ratings, error-detecting clinical data surveillance and analytics, and presented on these topics as well as systemic strategies for reducing the placebo and nocebo effects at Investigators’ Meetings. His expertise also extends to psychiatric scale management services, writing and editing clinical trial protocols, integrating regulatory compliance matters with rater training programs, and producing various scale training videos. Further, Dr. Cohen’s research has generated multiple presentations at several international pharmaceutical conferences on such topics as placebo and nocebo effect reduction methodologies, execution of pragmatic rater training programs, electronic data capturing devices, and methodological implications of psychiatric measures within clinical trials. Dr. Cohen’s research on methodologies to reduce the placebo and nocebo effects within clinical trials continues at HRI, where he and the other HRI Science Division team members empirically investigate and present at industry conferences on this crucial topic area.